Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
Astri Fjelde Maaland(University of Oslo), Jostein Dahle(Oslo University Hospital), Véronique Pascal(Nordic Nanovector (Norway)), Adam O’Shea(Nordic Nanovector (Norway)), Helèn Heyerdahl(Nordic Nanovector (Norway)), Bergthóra Eiríksdóttir, Arne Kolstad(Oslo University Hospital), Jan Terje Andersen(Oslo University Hospital)
Cited by 16
Related Papers
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
|Frontiers in Immunology|2015|297
DISTRIBUTION OF 5‐AMINOLEVULINIC ACID‐INDUCED PORPHYRINS IN NODULOULCERATIVE BASAL CELL CARCINOMA
|Photochemistry and Photobiology|1995|181